CRVS Corvus Pharmaceuticals, Inc.

Nasdaq corvuspharma.com


$ 7.37 $ -0.04 (-0.52 %)    

Tuesday, 04-Nov-2025 17:25:52 EST
QQQ $ 615.11 $ -4.04 (-0.65 %)
DIA $ 470.25 $ 0.57 (0.12 %)
SPY $ 672.36 $ -0.79 (-0.12 %)
TLT $ 90.13 $ 0.15 (0.17 %)
GLD $ 362.19 $ -1.27 (-0.35 %)
$ 7.64
$ 7.40
$ 7.30 x 1
$ 7.93 x 1
$ 7.33 - $ 7.66
$ 2.54 - $ 10.00
1,194,857
na
570.57M
$ 1.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-25-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 03-19-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 03-28-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 03-10-2022 12-31-2021 10-K
17 11-01-2021 09-30-2021 10-Q
18 08-02-2021 06-30-2021 10-Q
19 04-29-2021 03-31-2021 10-Q
20 03-25-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 07-30-2020 06-30-2020 10-Q
23 04-30-2020 03-31-2020 10-Q
24 03-09-2020 12-31-2019 10-K
25 10-30-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-07-2019 12-31-2018 10-K
29 11-01-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-03-2018 03-31-2018 10-Q
32 03-01-2018 12-31-2017 10-K
33 11-02-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 03-10-2017 12-31-2016 10-K
37 11-03-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 corvus-pharma-q3-eps-012-beats-014-estimate

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14)...

 corvus-pharmaceuticals-to-present-final-phase-1-data-on-soquelitinib-for-rr-t-cell-lymphoma-at-ash-2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that final data from it...

 corvus-pharmaceuticals-presents-interim-data-from-the-phase-1b2-clinical-trial-of-ciforadenant-for-patients-with-metastatic-renal-cell-cancer-at-the-esmo-congress-2025-interim-data-shows-triplet-therapy-with-ciforadenant-ipilimumab-and-nivolumab-is-feasible-and-well-tolerated-longer-follow-up-with-patients-still-on-therapy-needed-to-determine-potential-benefit-of-blocking-adenosine-signaling

SOUTH SAN FRANCISCO, Calif.,, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage bi...

 barclays-initiates-coverage-on-corvus-pharma-with-overweight-rating-announces-price-target-of-16

Barclays analyst Etzer Darout initiates coverage on Corvus Pharma (NASDAQ:CRVS) with a Overweight rating and announces Price...

 corvus-pharma-q2-eps-010-beats-013-estimate

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13)...

 corvus-says-partner-angel-pharmas-ind-approved-by-cde-of-china-nmpa-to-initiate-phase-1b2-clinical-trial-of-soquelitinib-for-treatment-atopic-dermatitis-in-china

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND applicatio...

 corvus-pharma-to-present-preclinical-data-highlighting-potential-of-soquelitinib-to-treat-systemic-sclerosis-at-eular-2025-congress

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highli...

 corvus-pharma-announces-new-interim-data-from-randomized-double-blind-placebo-controlled-phase-1-clinical-trial-evaluating-soquelitinib-in-patients-with-moderate-to-severe-atopic-dermatitis

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2All three cohorts show separation from placebo with s...

 mizuho-maintains-outperform-on-corvus-pharma-lowers-price-target-to-11

Mizuho analyst Graig Suvannavejh maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $1...

 oppenheimer-reiterates-outperform-on-corvus-pharma-raises-price-target-to-17

Oppenheimer analyst Jeff Jones reiterates Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $15...

 why-is-corvus-pharmaceuticals-stock-soaring-on-friday

Corvus reported strong Phase 1 results for soquelitinib in atopic dermatitis, with early efficacy and no major safety concerns ...

 corvus-pharma-q1-eps-013-misses-012-estimate

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.1...

 corvus-pharmaceuticals-announces-data-from-cohorts-1-3-of-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-in-patients-with-moderate-to-severe-atopic-dermatitis

Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION